Fresolimumab Completed Phase 2 Trials for Malignant Pleural Mesothelioma (MPM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01112293Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma